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Phenotype and Functional Features 
of Human Telomerase Reverse 
Transcriptase Immortalized Human 
Airway Smooth Muscle Cells from 
Asthmatic and Non-Asthmatic 
Donors
J. K. Burgess  1,2,3,4, A. Ketheson3,4, A. Faiz1,5, K. A. Limbert Rempel6, B. G. Oliver3,7,  
J. P. T. Ward8 & A. J. Halayko6
Asthma is an obstructive respiratory disease characterised by chronic inflammation with airway 
hyperresponsiveness. In asthmatic airways, there is an increase in airway smooth muscle (ASM) 
cell bulk, which differs from non-asthmatic ASM in characteristics. This study aimed to assess the 
usefulness of hTERT immortalisation of human ASM cells as a research tool. Specifically we compared 
proliferative capacity, inflammatory mediator release and extracellular matrix (ECM) production 
in hTERT immortalised and parent primary ASM cells from asthmatic and non-asthmatic donors. 
Our studies revealed no significant differences in proliferation, IL-6 and eotaxin-1 production, or 
CTGF synthesis between donor-matched parent and hTERT immortalised ASM cell lines. However, 
deposition of ECM proteins fibronectin and fibulin-1 was significantly lower in immortalised ASM cells 
compared to corresponding primary cells. Notably, previously reported differences in proliferation and 
inflammatory mediator release between asthmatic and non-asthmatic ASM cells were retained, but 
excessive ECM protein deposition in asthmatic ASM cells was lost in hTERT ASM cells. This study shows 
that hTERT immortalised ASM cells mirror primary ASM cells in proliferation and inflammatory profile 
characteristics. Moreover, we demonstrate both strengths and weaknesses of this immortalised cell 
model as a representation of primary ASM cells for future asthma pathophysiological research.
Asthma is an obstructive respiratory disease that is characterised by airway hyper-responsiveness, airway 
obstruction and chronic inflammation1. Inflammation and structural changes, referred to as ‘airway remodelling’ 
are important features of asthma2,3. One prominent feature in the airway wall of asthmatics is an increased bulk 
of airway smooth muscle (ASM)4.
The ASM bundles are found in the submucosal layer where they wrap circumferentially around the airway5. 
In ASM derived from asthmatic donors compared to ASM cells from non-asthmatic donors in vitro cellular 
hyperplasia, in response to a proliferative stimulus, has been reported6,7. The ASM is not alone but connected to 
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a network of extracellular matrix (ECM) proteins. Typically, these proteins act as support structures for the cells, 
however, they are also biologically active and can influence aspects of the ASM’s cellular functions8–13.
The ASM derived from asthmatics produces an altered inflammatory profile of cytokines and chemokines 
and has altered ECM protein production13–17. These changes in the inflammatory profile are thought to poten-
tiate the inflammatory nature of asthma, while the altered matrix is able to feedback back to the cells within the 
microenvironment to influence other cellular functions. In this study we focussed on investigating certain key 
cytokines (including Interleukin (IL)-618–22 and Eotaxin-123), growth factors (Connective tissue growth factor 
(CTGF)24,25) and ECM proteins (fibronectin26 and fibulin-117) previously reported to be increased in asthma. 
Interleukin (IL)-6 is a key inflammatory cytokine that has been characterised in asthma. It is mainly produced by 
innate immune cells, such as macrophages, but it can also be derived from ASM cells, with greater production by 
cells from asthmatic than nonasthmatic donors18–22. Eotaxin-1, an important chemokine in asthma that attracts 
eosinophils to sites of inflammation in the airways27, is also a key difference seen between primary asthmatic 
and non-asthmatic ASM cells. Chan et al. reported asthmatic ASM cells released greater amounts of eotaxin-1 in 
response to a variety of inflammatory stimuli23. CTGF has been shown to be increased in asthmatic patients. With 
angiogenic and fibrotic properties, the high levels of CTGF can result in airway remodelling of the asthmatic air-
way25. In terms of the ASM, pre-treatment of ASM cells with transforming growth factor-beta (TGF-β) stimulates 
the release of CTGF. Additionally, asthmatic ASM cells release significantly greater amounts of CTGF compared 
to non-asthmatic cells24,25. Fibronectin is a pro-proliferative ECM protein that is deposited in greater amounts 
by asthmatic ASM cells, particularly following TGF-β induction26. Fibulin-1 is another pro-fibrotic ECM protein 
that has been shown to be increased in asthmatic serum and bronchoalveolar lavage (BAL) fluid17. The same study 
reported that TGF-β stimulated asthmatic ASM cells deposited increased amounts of fibulin-1 in the matrix than 
non-asthmatic cells.
These changes in fundamental functional properties of ASM from asthmatics support an important role in 
disease pathophysiology. The gold standard model for in vitro research of ASM in asthma is primary culture 
of cells from human donors. Primary cells are isolated from ASM bundles – dissected from human lung tissue 
obtained by lung resection, transplant or biopsy - and expanded in culture28. They provide a model for studying in 
vivo cellular responses29, however, major limitations in routinely using primary ASM cell cultures include obtain-
ing primary tissue, particularly from asthmatics, and the limited number of cell doublings that ASM cells can 
undergo before they lose fundamental phenotypic features of ASM, change morphology or undergo senescence.
Immortalisation of primary ASM cells derived from individuals with and without asthma was originally 
described by Gosens et al.30. Through stable ectopic expression of human telomerase reverse transcriptase 
(hTERT), the lifespan of these cells was extended. Moreover, fundamental phenotypic features of the cells were 
maintained through multiple passages and cell doublings that far exceed that of primary ASM cell cultures, thus 
providing a versatile resource for experimentation.
Despite their continued use, there remain gaps in understanding of the strengths and limitation of using 
hTERT immortalised ASM cells for fundamental experimentation. To date no studies have directly compared the 
features of hTERT ASM cells to those of donor-matched primary ASM cell lines. In the current study we directly 
address whether hTERT immortalised ASM cell lines retain unique features of parent primary ASM cells, using 
cells derived from asthmatic and non-asthmatic donors.
Materials and Methods
Primary Airway Smooth Muscle Cell Isolation and culture. Approval for experiments with human 
lung tissue was provided by the Ethics Review Committee of the South West Sydney Area Health Service, St 
Vincent’s Hospital Sydney, Strathfield Private Hospital, Royal Prince Alfred Hospital and the University of Sydney 
Human Research Ethics Committee, as well as the South East London Research Ethics Committee (REC reference 
number: 10/H0804/66), and the Human Research Ethics Committee of the University of Manitoba. All clinical 
procedures conformed to the standards set by the latest Declaration of Helsinki.
Primary human ASM cells were obtained through dissection of donated lung tissue following deep endo-
bronchial biopsies from volunteers who provided written informed consent, as described previously6,17. Healthy 
volunteers were selected based on a life-long absence of respiratory symptoms, and, where possible, lung func-
tions within normal limits. Moderate asthmatics were selected based on the presence of typical symptoms over at 
least two years, a minimum of 12% reversibility, FEV1 < 80% of predicted for age, and/or a bronchoconstrictor 
response to a methacholine challenge of <8 mg/ml. Patients currently receiving leukotriene receptor antagonists, 
smokers and pregnant/lactating females were excluded. One non-asthmatic (healthy) ASM cell line was sourced 
from a lung donated for transplantation. Though it was deemed unsuitable for transplant, it was not from an 
individual with any known lung pathology (Table 1).
Cells were established at both the University of Sydney and Kings College London. Primary ASM cells under-
went hTERT immortalisation at the University of Manitoba as previously described30. The phenotype of all ASM 
cell lines established in both laboratories was confirmed using immunofluorescence and light microscopy to 
identify the distinct hill and valley pattern of growth. Cells were stained with antibodies against α-smooth muscle 
actin and calponin while omission of the primary antibody was used as a control, as previously published31,32.
Primary ASM cell cultures were only used between passage numbers 2 and 8, while corresponding hTERT 
ASM cell lines were used up to passage number 20.
For all cultures, ASM cells were seeded into multi-well plates at a density of 3.2 × 103 cells/ml in 10% foetal 
bovine serum (FBS) (DSKH, Melbourne, Australia), 1% antibiotics supplemented Dulbecco’s modified Eagle 
medium (DMEM) (Life Technologies, Carlsbad, CA, USA) for 24 hours. Aspiration of seeding media was fol-
lowed by the addition of quiescing media (0.1% bovine serum albumin (BSA) (Sigma Aldrich, St Louis, Missouri, 
USA), 1% antibiotics in DMEM), which was left for three days. Stimulations appropriate for the outcome measure 
were then added.
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Proliferation. The proliferation of the ASM cells in the presence of 5% FBS was assessed via manual cell 
counting on days 0, 3, 5 and 7 post treatment, as previously6.
Detection of IL-6 and Eotaxin-1 by ELISA. ASM cells were seeded in 6 well plates at 3.2 × 103 cells/ml 
in 10% foetal bovine serum (FBS) (DSKH, Melbourne, Australia), 1% antibiotics supplemented Dulbecco’s mod-
ified Eagle medium (DMEM) (Life Technologies, Carlsbad, CA, USA) for 24 hours, followed by quiescing three 
days in 0.1% bovine serum albumin (BSA) (Sigma Aldrich, St Louis, Missouri, USA), 1% antibiotics in DMEM 
prior to being treated with 10 ng/ml IL-1β or 10 ng/ml TNF-α. Supernatant samples were collected over a 24 hour 
time course (0, 8, 16 and 24 hours) and stored in aliquots at −20 °C until analysis. IL-6 (BD Biosciences, Franklin 
Lakes, NJ, USA) and eotaxin-1 (R&D Systems, Minneapolis, MN, USA) were detected with an enzyme linked 
immunosorbent assay (ELISA) kit, according to the manufacturers’ instructions.
Detection of cell associated CTGF by ELISA. ASM cells were seeded in 96 well plates as described above, 
then treated with 10 ng/ml TGF-β1 for 24 hours. Supernatant was removed, the plate was allowed to dry over-
night, then stored at −20 °C in an airtight container until CTGF was detected using a cell surface ELISA tech-
nique as described previously33.
Detection of Fibronectin and Fibulin-1 by ELISA. ASM cells were seeded into 96 well plates as 
described above then treated with 10 ng/ml TGF-β1 for 48 and 72 hours. Supernatant was removed and wells were 
washed with PBS/0.05% Tween 20 three times. Thereafter, the ECM was exposed by treating the cell layer with 
ammonium hydroxide (Sigma Aldrich) for 30 minutes at 37 °C. After viewing the plate under a light microscope 
to confirm cell detachment, the plate was stored in PBS at −20 °C until required.
Fibronectin (FN) and Fibulin-1 (FBLN-1) ELISAs were conducted as described previously34–36. Briefly, the 
FN ELISA included standards (BD Biosciences) serially diluted in 0.1% BSA 1% antibiotic supplemented DMEM 
(2000 ng/ml to 31.25 ng/ml) added in duplicate to the plate which was left at 4 °C overnight on an orbital mixer. 
The following day both the FN and FBLN-1 ELISA plates were washed, blocked and FN primary antibody, 
mouse anti-human plasma fibronectin C-Terminal (Chemicon, Billerica MA USA) diluted 1:500 or FBLN-1 
primary antibody (Santa Cruz) diluted 1:3000 or isotype control antibody, mouse IgG2a (DAKO) were added. 
Secondary antibody (rabbit anti-mouse Ig horseradish peroxidase (DAKO) for the FN plate and biotin conjugated 
chicken anti-mouse (Life Technologies) for the FBLN-1 plate both diluted 1:500 in reagent diluent) followed by 
2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS, Life Technologies) substrate solution for the FN 
plate; or streptavidin-HRP followed by TMB substrate solution for the FBLN-1 plate. The FN plate was read at 
405 nm while the FBLN-1 plate read at 450 nm and 570 nm on the Wallac 1420 microplate reader. The linear part 
of the FN standard was used to determine the concentration of FN deposited by cells. Comparison of the optical 
densities of the control samples to the treatment samples was used for assessing the FBLN-1 production.
Statistical analyses. Statistical tests and graph plotting were conducted using GraphPad Prism 7 (GraphPad 
Software, La Jolla, California USA). A two way ANOVA with Sidak’s multiple comparisons test was used to assess 
significance over time, or in response to treatment and to compare immortalised and primary ASM cells. A prob-
ability (p) value of <0.05 was considered statistically significant.
Results
Comparison of hTERT immortalised ASM cells and primary ASM cells. In our initial studies, 
hTERT immortalised ASM cell cultures were compared to donor-matched primary ASM cell cultures. No differ-
ences were observed in the morphological characteristics of the primary and corresponding hTERT immortalised 
ASM cell cultures using phase contrast microscopy (Fig. 1).
Proliferation. The number of immortalised ASM cells increased steadily over 7 days following treatment with 
5% FBS (Fig. 2a). A significant increase was seen at days 3 (p < 0.01), 5 (p < 0.01) and 7 (p < 0.001), compared 
to day 0 and also the previous count day. Similarly, primary ASM cells responded to treatment with 5% FBS with 
significant increases at day 3 (p < 0.05), 5 (p < 0.01) and 7 (p < 0.01). Of note, there were no significant differences 
Patient# Age Sex
Health 
Status Sample Country of Origin
Primary or 
Immortalised
1 22 F Healthy Biopsy Australia Both
2 69 M Healthy Biopsy Australia Both
3 21 M Asthmatic Biopsy Australia Both
4 48 M Healthy Donor lung Australia Both
5 45 M Asthmatic Biopsy Australia Both
6 33 M Asthmatic Biopsy Australia Both
7 36 M Asthmatic Biopsy United Kingdom Only Immortalised
8 39 M Asthmatic Biopsy United Kingdom Only Immortalised
9 37 M Asthmatic Biopsy United Kingdom Only Immortalised
10 37 F Healthy Biopsy United Kingdom Only Immortalised
11 28 F Healthy Biopsy United Kingdom Only Immortalised
Table 1. Patient Characteristics.
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between cell numbers in hTERT immortalised and primary ASM cell cultures at any count day (Fig. 2). Moreover, 
the individual proliferative responses of primary and immortalised cell cultures from the same donor were 
directly correlated (Fig. 2b).
Inflammatory Profile. hTERT immortalised and primary ASM cell cultures exhibited similar basal (control) lev-
els of IL-6 and eotaxin-1 production (Fig. 3). IL-6 and eotaxin-1 release was significantly increased by IL-1β and 
TNF-α in hTERT ASM cell cultures (p < 0.001 and p < 0.01 respectively for both treatments) (Fig. 3a). A similar 
induction of IL-6 release was measured for primary ASM cell cultures (p < 0.001 for both treatments), however, 
only IL-1β induced a significant increase in eotaxin-1 production in primary ASM cultures (p < 0.05) (Fig. 3b). 
Of note, despite this difference, cytokine-induced IL-6 and eotaxin-1 release was similar in immortalised and 
Figure 1. Phase contrast micrographs of primary human ASM cell cultures and corresponding hTERT 
immortalized human ASM cell cultures generated from an asthma donor and non-asthma donor. Typical 
images from subconfluent and confluent cultures grown in culture media supplemented with FBS are shown. 
The primary cell culture shown was at Passage 1, and the hTERT cell line shown was imaged during Passage 5 
after immortalization. The white scale bar shown = 50 µm.
Figure 2. Proliferative response of hTERT immortalised and primary ASM cells. hTERT immortalised ASM 
(n = 6) and primary ASM (n = 6) cells from the same donor were treated with 5% FBS for 7 days. Cell number 
was assessed by manual cell counting. (a) All data are presented as the mean +/− standard error of the mean 
(SEM). A two way ANOVA with Sidak’s multiple comparisons test was used to assess significance over time and 
compare immortalised and primary cells. Significance difference compared to previous count day *p < 0.05, 
**p < 0.01 and ***p < 0.001. (b) correlation of cell counts of primary and immortalised cells from the same 
donor.
www.nature.com/scientificreports/
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primary ASM cell cultures. The amounts of IL-6 and eotaxin-1 produced by donor-matched hTERT immortalised 
and primary ASM cell cultures were not different (Fig. 3c,d).
Growth Factors. Immortalised ASM cell cultures were unique in that they showed a significant increase in 
CTGF production following TGF-β treatment (p < 0.05), whereas this response was not evident in the primary 
ASM cell cultures (Fig. 4a). Immortalised and primary ASM cell cultures derived from the same donor showed 
no variation in the amount of CTGF produced (Fig. 4b).
ECM Protein Production. Both immortalised and primary ASM cell cultures exhibited significantly increased FN pro-
duction following exposure to TGF-β1 (p < 0.0002, p < 0.05) (Fig. 5a and c). In contrast, we only observed a significant 
increase in TGF-β1-induced FBLN-1 deposition in primary ASM cell cultures (p < 0.01 for 48 h, p < 0.05 for 72 h), suggest-
ing that FBLN-1 deposition in immortalised ASM cell cultures is refractory to TGF-β1 exposure (p < 0.05) (Fig. 5b and d). 
Compared to the primary ASM cell cultures, the immortalised cells produced significantly less FN in untreated (p < 0.01 
for 48 h, p < 0.05 for 72 h) and TGF-β1 treated (p < 0.001 for 48 h, p < 0.01 for 72 h) conditions (Fig. 5a and c). However, 
there were no significant differences detected in FBLN-1 deposition between immortalised and primary ASM cell cultures 
under control conditions or after TGF-β1 exposure (Fig. 5b and d). Comparing donor-matched hTERT immortalised and 
primary ASM cell cultures directly, we observed that FN and FBLN-1 production was lower in immortalised cell lines in 
control conditions and after TGF-β1 exposure (Fig. 5e and f).
Comparison of immortalised asthmatic and non-asthmatic ASM cells. Based on our observa-
tions comparing donor-matched primary and hTERT ASM cell cultures, we next determined whether previously 
described functional differences between primary ASM cell cultures from asthmatic and non-asthmatic donors 
are maintained in hTERT immortalised ASM cell cultures generated from these parent cell lines.
Proliferation. Immortalised ASM cell cultures from both asthmatic and non-asthmatic patients showed a significant 
increase in cell number over 7 days in media supplemented with 5% FBS. There was a significant increase in cell num-
ber between each count day for asthmatic (p < 0.001 for all days) and non-asthmatic (p < 0.05 for all days) hTERT ASM 
cells. Importantly, by day 5 (p < 0.05) and day 7 (p < 0.001) there were significantly higher numbers of cells in cultures 
of asthmatic hTERT ASM cell lines compared to cultures of hTERT ASM cells from non-asthmatic donors (Fig. 6). This 
finding indicates that a hyper-proliferative phenotype is retained in asthmatic ASM cells after hTERT immortalization.
Figure 3. IL-6 and eotaxin-1 production from hTERT immortalised and primary ASM cells. Comparison of 
IL-6 (a) and eotaxin-1 (b) production from hTERT immortalised (n = 6) and primary (n = 6) ASM cells from 
the same donors following 24 hour stimulation with 10 ng/ml IL-1β or 10 ng/ml TNF-α. All data are presented 
as the mean +/− SEM. Statistical analysis was performed using a two way ANOVA with Sidak’s multiple 
comparisons test for changes in IL-6 or eotaxin production due to treatment and comparison of immortalised 
and primary cells. Significance difference due to treatment *p < 0.05, **p < 0.01 and ***p < 0.001. Correlation 
of IL-6 (c) and eotaxin (d) release from primary and immortalised ASM cells from the same donor.
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Inflammatory Profile. Although IL-6 release under basal conditions was not different in hTERT ASM cultures 
from asthmatic and non-asthmatic donors, under basal conditions eotaxin-1 release was significantly higher in 
hTERT immortalised asthmatic ASM cell cultures (p < 0.05) (Fig. 7). Compared to untreated control conditions, 
treatment with IL-1β and TNF-α induced a significant release of both IL-6 (p < 0.001) and eotaxin-1 (p < 0.01) 
from cultures of immortalised asthmatic ASM cell cultures (Fig. 7). In immortalised non-asthmatic ASM cell 
cultures, while IL-6 release was significantly increased in response to IL-1β and TNF-α treatment (p < 0.001), 
surprisingly, the increase in eotaxin-1 was not significant (Fig. 7b). Importantly, IL-1β-induced release of IL-6 
was significantly greater for immortalised asthmatic ASM cell cultures compared to non-asthmatic ASM cell 
cultures (p < 0.01) (Fig. 7a), whereas we observed no difference in TNF-α-induced release of IL-6 in asthmatic 
and non-asthmatic ASM cell cultures. Furthermore, both IL-1β- and TNF-α-induced release of eotaxin-1 was 
markedly greater in immortalised asthmatic ASM cell cultures compared to non-asthmatic ASM cells (p < 0.001 
for both treatments) (Fig. 7b).
Growth Factors. There was a significant increase in CTGF production in response to TGF-β1 for immortalised 
asthmatic ASM cell cultures (p < 0.01) (Fig. 8). However, the same increase was not evident in the immortalised 
non-asthmatic ASM cell cultures. This difference manifested as greater cumulative TGF-β1-induced synthesis 
of CTGF by hTERT immortalised asthmatic ASM cell cultures compared to non-asthmatic ASM cell cultures 
(p < 0.05).
Figure 4. CTGF production from hTERT immortalised and primary ASM cells. Production of CTGF from 
hTERT immortalised (n = 6) and primary (n = 6) ASM cells following 24 hour treatment with 10 ng/ml TGF-β. 
(a) Data are presented as the mean +/− SEM of absorbance values (450 nm) in presence of CTGF Ab. A two 
way ANOVA with Sidak’s multiple comparisons test was used to detect differences between control and TGF-β 
treated groups and to compare immortalised ASM to primary ASM. Significant difference due to treatment 
*p < 0.05. (b) Correlation of CTGF production from primary and immortalised ASM cells from the same 
donor.
www.nature.com/scientificreports/
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ECM Protein Production. TGF-β1 treatment induced an increase in FN and FBLN-1 deposition in immortal-
ised asthmatic ASM cell cultures (FN 48 hrs p < 0.001, 72 hrs p < 0.01; FBLN-1 48 & 72 hrs p < 0.05) (Fig. 9). In 
immortalised non-asthmatic ASM cells, TGF-β1 also induced significant FN deposition at both 48 and 72 hours 
(48 hrs p < 0.05, 72 hrs p < 0.01), however, compared to control conditions, TGF-β1 only induced significant 
FBLN-1 accumulation 48 hrs after exposure (p < 0.05). Interestingly, for all cultures maximum FN and FBLN-1 
accumulation was attained within 48 hrs TGF-β1 treatment, as there was no additional deposition at 72 hrs treat-
ment. In contrast to enhanced release of IL-6, eotaxin-1 and CTGF, we observed no difference in the deposition 
of FN or FBLN-1 by immortalised ASM from asthmatic or non-asthmatic donors (Fig. 9).
Discussion
This study shows for the first time that hTERT immortalised ASM cells provide a useful tool for characteris-
ing mechanisms relating to differences in tissue inflammatory responses in asthma, as they mirror unique 
hyper-secretory characteristics of primary ASM cells from asthmatic donors13–17. Using donor-matched 
parent and immortalised cell lines, we reveal that hTERT immortalised ASM cell cultures retain a similar 
proliferative response, inflammatory profile and growth factor production as parent primary ASM cell cul-
tures. Despite continuity in these important pathophysiological functions, we also observed that hTERT 
Figure 5. Fibronectin and fibulin-1 deposition by hTERT immortalised and primary ASM cells. FN and 
fibulin-1 deposition from hTERT immortalised (n = 6) and primary (n = 6) ASM cells in response to treatment 
with 10 ng/ml TGF-β. (a) FN and (b) fibulin-1 after 48 hours treatment and (c) FN and (d) fibulin-1 after 
72 hours treatment with TGF-β. All data are presented as the mean +/− SEM. Statistical analysis performed 
using a two way ANOVA with Sidak’s multiple comparisons test for comparison of untreated to treated cells, to 
detect differences across time and also to detect significant differences between immortalised and primary cells. 
Significance between untreated and treated cells *p < 0.05 and **p < 0.01. Significance between immortalised 
and primary cells #p < 0.05, ##p < 0.01 and ###p < 0.001. Correlation of FN (e) and fibulin-1 (f) deposition after 
72 hours treatment with TGFβ from primary and immortalised cells from the same donor.
www.nature.com/scientificreports/
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immortalisation did not retain a full repertoire of ECM protein deposition, as immortalised ASM cells exhib-
ited hypo- or refractory-responsiveness to TGF-β1-induced FN and FBLN1 deposition, indicating that there 
are some limitations in using these cells to assess all aspects of airway matrix remodelling. This study also com-
pared immortalised ASM cells derived from asthmatic and non-asthmatic subjects, and overall, our new data 
demonstrate that many previously established differences in functional characteristics of ASM from asthmatic 
subjects are maintained after hTERT immortalisation. While we did not compare the responses of the primary 
asthmatic and non-asthmatic cells in this study, some of these cells had been used as part of previous studies in 
which differences in the responses measured in this study were reported. The current data reflect prior studies 
that describe hyper-proliferative capacity of primary ASM cells derived from asthmatic subjects14,15, as well as 
hyper-secretory inflammatory mediator and growth factor release of primary human asthmatic ASM cell cul-
tures18–22,27. Conversely, we did not observe that hTERT immortalised asthmatic ASM cell cultures retained char-
acteristic differences in FN and FBLN1 synthesis seen in primary ASM cell cultures from asthmatic donors14,17,26. 
Collectively, our observations demonstrate that hTERT immortalisation of human ASM cells is an effective 
approach to generate a sustainable and reliable in vitro system to dissect key elements of ASM pathobiology in 
asthma. In a separate study we have undertaken a systematic assessment of the method of immortalising primary 
ASM cells, which includes only a general assessment of functional and phenotypic properties of human hTERT 
Figure 6. Comparison of proliferation between immortalised ASM of asthmatic and non-asthmatic patients. 
hTERT immortalised nonasthmatic ASM (n = 5) and asthmatic ASM (n = 6) cells were treated with 5% FBS for 
7 days. Cell number was assessed by manual cell counting. All data are presented as the mean +/− SEM with 
statistical analysis via a two way ANOVA with Sidak’s multiple comparisons test. Analysis was performed to 
detect differences between each count day and asthmatic and non-asthmatic ASM cell numbers. Significant cell 
number increase *p < 0.05 and ***p < 0.001. Significance between immortalised asthmatic and non-asthmatic 
cells #p < 0.05 and ###p < 0.001.
Figure 7. IL-6 and eotaxin-1 release from immortalised non-asthmatic and asthmatic ASM cells. (a) IL-6 
and (b) eotaxin-1 release from ASM from immortalised non-asthmatic (n = 5) and asthmatic (n = 6) donors 
in response to 24 hour treatment with 10 ng/ml IL-1β or 10 ng/ml TNF-α. All data are presented as the mean 
+/− SEM. A two way ANOVA with Sidak’s multiple comparisons test was used to detect differences between 
asthmatic and non-asthmatic cells and treatment groups. Significance between asthmatic and non-asthmatic 
cells #p < 0.05, ##p < 0.01, ###p < 0.001. Significance difference induced by treatment compared to control 
**p < 0.01, ***p < 0.001.
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ASM cell lines, but does not directly test whether hTERT immortalisation maintains the unique, heterogeneous 
nature inherent to ASM primary cell cultures from different donors (submitted July 2017).
Immortalised ASM cells mirrored primary ASM cell cultures in their response to a pro-proliferative stimulus, 
5% FBS, inducing similar proliferation in immortalised and primary ASM over the course of a typical single cell 
culture passage (7 days). Immortalised cell cultures also behaved the same as corresponding primary ASM cell 
cultures in terms of cytokine and chemokine release with no significant variation in IL-6 and eotaxin-1 release 
between the two cell models. Of mention, the level of eotaxin-1 released by the primary cells in response to TNFα 
and IL-1β did not differ. So while the induction of eotaxin-1 was significantly different from the control levels 
in the immortalized ASM cells but not in the primary cells in the current data series, we do not believe this rep-
resents a differential response between these cells. It is important to note that “hTERT immortalisation” reflects 
the induction of a senescence resistant state, but is not associated with cell transformation per se, thus cells retain 
a requirement for adherence-dependent growth and are refractory to acquisition of a senescence-associated 
hyper-secretory phenotype37,38.
Figure 8. CTGF production from immortalised asthmatic and non-asthmatic ASM cells. CTGF production 
from immortalised non-asthmatic (n = 5) and asthmatic (n = 6) ASM cells following 24 hour treatment with 
10 ng/ml TGF-β. All data are presented as the mean +/− SEM with statistical analysis via a two way ANOVA 
with Sidak’s multiple comparisons test. Analysis was performed between control and treatment groups and 
immortalised asthmatic and non-asthmatic ASM cells. Significance between control and treatment **p < 0.01. 
Significance between immortalised asthmatic and non-asthmatic samples #p < 0.05.
Figure 9. Fibronectin and fibulin-1 deposition by immortalised asthmatic and non-asthmatic ASM cells. FN 
and FBLN-1 deposition from immortalised non-asthmatic (n = 5) and asthmatic (n = 6) ASM cells after 48 hrs 
(a and b respectively) or 72 hrs (c and d respectively) in response to treatment with 10 ng/ml TGF-β. All data are 
presented as the mean +/− SEM. Statistical analysis via a two way ANOVA with Sidak’s multiple comparisons 
test was performed to test differences between control and treatment groups and immortalised asthmatic and 
non-asthmatic ASM cells. Significance as a result of treatment is represented by **p < 0.01 and ***p < 0.001.
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The production of CTGF from immortalised ASM cells was also similar to that of corresponding primary 
ASM cells, however, we found that the responsiveness of primary ASM cells TGF-β1-induced CTGF production 
was generally lower than that we have reported in previous studies24,25. This may be related to us employing an 
ELISA method for cell surface, not intracellular, detection in the current study, compared to immunoblotting 
assays used in earlier work. Nonetheless, basal and TGF-β1-stimulated CTGF production was similar between 
immortalised and primary ASM cells.
The major discrepancy we observed between immortalised and primary human ASM cell cultures was in the 
production of ECM proteins. FN production was significantly lower in immortalised ASM cells compared to the 
corresponding primary ASM cells. Similarly, there was a significant variation between immortalised and primary 
ASM cell cultures for FBLN-1 deposition following TGF-β1 exposure. One role of the ECM is to provide the cells 
with survival signals, through integrin surface receptors, to prevent programmed cell death induced following 
detachment from ECM (anoikis). Disruption of communication between the ASM cells and ECM elements such 
as FN or FBLN1 can result in cell death and alterations in the ECM can also change the growth patterns of ASM 
cells9,13,39. It is possible that the process of hTERT immortalisation of ASM cells may disrupt anoikis program-
ming, thus homeostatic requirements for ECM deposition may be affected. Indeed endothelial cells that acquire 
anoikis resistance display decreased expression of fibronectin and other ECM proteins and an alteration in their 
integrin repertoire40. Of note integrin β1 is a downstream target of hTERT41 suggesting disruption of this integrin 
may occur in the immortalised ASM cells.
The ECM also has a role in mediating proliferation and the production of cytokines, chemokines and growth 
factors13,42–44. Since these characteristics were not different between immortalised and primary ASM cells, the 
altered deposition of ECM proteins in immortalised cells does not appear, in this case, to be a critical determinant 
of proliferation or inflammatory mediator release. Given that FN was induced by TGF-β1, albeit at a lower level 
than seen in the primary cells, it is possible that the reduction in ECM expression in the immortalised ASM cells 
did not reach a threshold necessary to influence these parameters. Alternately, other pathways, such as mamma-
lian target of rapamycin (mTOR)/Akt pathway, peroxisome proliferator-activated receptor gamma (PPAR γ) or 
mitogen-activated protein kinases (MAPKs)45–51, may maintain proliferative function and inflammatory profiles 
in immortalised ASM cells.
Once the validity of the immortalised ASM cells as a model for primary ASM cells had been confirmed we 
also undertook a comparison of hTERT immortalised ASM cell cultures from asthmatic and non-asthmatic 
donors. Our results showing enhanced proliferation of immortalised asthmatic ASM cells are consistent with 
prior studies that compared primary asthmatic and non-asthmatic human ASM cell cultures6,7. Immortalised 
asthmatic ASM cells only had significantly increased IL-1β-induced IL-6 production compared to non-asthmatic 
cells, but there was no difference in TNF-α induced IL-6 production. Several studies report that TNF-α exposure 
increases production of IL-6 by human ASM cells19,21, but, there are few studies that compare the IL-6 production 
between asthmatic and non-asthmatic ASM cells, with only one study reporting that IL-6 release was greater 
from asthmatic compared to non-asthmatic ASM cells after rhinovirus exposure22. There were greater amounts 
of basal and IL-1β- or TNF-α-induced eotaxin-1 produced by immortalised asthmatic ASM cell cultures com-
pared to immortalised non-asthmatic ASM cells. This finding is fully consistent with previous studies that report 
eotaxin-1 hypersecretion in primary asthmatic ASM cell cultures23. Our observation using immortalised cultures 
that CTGF production is greater in TGF-β1 treated asthmatic ASM cells compared to non-asthmatic ASM cells 
is also consistent with our previous studies24,25 in which we illustrated the importance of the asthmatic ASM in 
regulating the enhanced angiogenesis in the airways, through release of CTGF and other factors12,24,33,52,53.
In contrast to the release of cytokines, chemokines and growth factors, our comparison of ECM protein depo-
sition between immortalised asthmatic and non-asthmatic ASM cell cultures revealed no significant differences. 
These findings are not reflective of previous work, using primary ASM cells, in which TGF-β induced FN bio-
synthesis is greater in ASM from asthmatic donors compared to those from non-asthmatic donors26. As already 
noted, this apparent disparity between the data in the current study and previous reports suggests that capacity 
for FN and FBLN-1 deposition is affected by the hTERT immortalisation process. As a caveat, we cannot specif-
ically rule out the possibility that for the group of individual primary cell lines used to generate hTERT immor-
talised ASM cell lines in this study, there were also no differences FN and FBLN-1 output, as we did not measure 
this in the current study, and some degree of variability can exist. However, our previous work with some of these 
cells suggests that the latter possibility is unlikely.
A limitation of this study is that we did not directly monitor hTERT incorporation in the ASM cell lines tested. 
Moreover, we did not determine if there are any differences in the expression of ectopic hTERT in immortalised 
ASM cells from asthmatic and non-asthmatic patients. Of note, the immortalisation process uses lentiviral vec-
tors to transduce primary ASM cells and promote homologous recombination of copies of the hTERT. To reduce 
inter-culture and inter-cell disparity in hTERT incorporation, cells are subjected to severe antibiotic selection, 
thus only those cells that incorporate multiple copies of hTERT will exhibit sufficient resistance to selection with 
high concentrations of G418 antibiotic. Nonetheless, we cannot rule out the possibility that there may be differ-
ences between hTERT cell lines or individual cells in hTERT cell lines due to disparate ectopic hTERT expression. 
The cell lines tested were also not expanded from single clones but rather represented a mixed population of cells. 
Our studies did not address potential effects that differing expression of hTERT may specifically have on prolifer-
ation rates, inflammatory and growth factor production, and ECM deposition.
In conclusion, this study validates hTERT immortalised ASM cell lines as a reliable and sustainable resource 
for use in future investigation to elucidate the role of the ASM in asthma pathophysiology. hTERT immortal-
ised ASM cells retain proliferation, inflammatory cytokine and chemokine release and growth factor production 
characteristics of the primary ASM cell cultures from which they are generated. However, some caution is needed 
with respect to capacity for biosynthesis of FN and FBLN-1; though expression of these ECM proteins is retained 
in immortalised ASM cell lines, the capacity for biosynthesis san responsiveness to pro-fibrotic growth factor 
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exposure appears to be dampened by hTERT immortalisation. In the future, the use of increasingly sensitive 
methods for the detection of ECM proteins may provide insight about appropriate use of hTERT immortalised 
ASM cells in this area of research.
Overall, this study has provided the foundation for the introduction of new valuable immortalised ASM cell 
lines from asthmatic and non-asthmatic human donors. This initial validation will pave the way forward ena-
bling future studies using more complex in vitro systems that could, for example, involve 3D bio-printing, with 
co-culture of immortalised ASM with fibroblasts and epithelial cells, to generate a structure that more closely 
reflects the in vivo airway for the investigation of mechanisms controlling asthma pathophysiology.
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